class action lawsuit

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

BlackRock faces securities fraud investigation after implementing 5% quarterly redemption caps on HPS Corporate Lending Fund, triggering 7.69% stock decline.

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

Microvast ($MVST) plunged 34% after reporting $96.5M revenue (29% below consensus) and 1% gross margins, triggering securities fraud investigation by Pomerantz LLP.

Pomerantz LLP investigates Freshpet for potential securities fraud tied to unsupported 'human grade' pet food claims, triggering sharp stock decline.

Pomerantz Law Firm investigates $CFLT over undisclosed AI customer spending reduction that caused stock to crash 32.86% on July 31, 2025.

Goldman Sachs sued as lead underwriter for allegedly failing to disclose 39% surge in Navan's marketing costs before October 2025 IPO, resulting in 63% stock collapse.

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

$LAKE faces class action suit alleging executives misrepresented acquisition integration and hid operational problems, leading to 39% stock crash.

Pomerantz Law Firm files class action against Enphase Energy over alleged misstatements regarding inventory management and federal solar tax credit impacts. Stock fell 15.15% after weak Q3 guidance.

Schall Law Firm seeks $PSIX investors for class action over alleged false statements on data center business and manufacturing costs. Deadline: May 19, 2026.

Navan investors face April 2026 deadline to join class action over allegedly misleading IPO disclosures. Stock has fallen 63% after undisclosed 39% expense increase announcement.

Schall Law Firm seeks class action participants against Gartner ($IT) for alleged securities fraud involving false statements on seasonality risks and tariff impacts. Deadline May 18, 2026.

Schall Law Firm launches securities fraud class action against $GEMI, alleging misleading statements about crypto platform and expansion plans since September 2025 IPO.

Zynex faces securities class action lawsuit following bankruptcy, $85M fraud settlement, and delisting after alleged systematic overbilling scheme.

ODDITY Tech ($ODD) faces securities fraud lawsuit after 49% stock plunge over alleged non-disclosure of advertising algorithm changes that spiked customer acquisition costs.

Mereo BioPharma faces class action lawsuit alleging misrepresentations regarding failed Phase 3 clinical trials, with lead plaintiff deadline April 6, 2026.

BlackRock TCP Capital Corp. (TCPC) faces class action lawsuit alleging securities fraud over materially false portfolio valuations and overstated net asset value between November 2024 and January 2026.